Australia’s CSL buying ‘Vifor Pharma’

Australia’s sole manufacturer of AstraZeneca Plc’s Covid-19 vaccine, agrees to buy Swiss drug maker ‘Vifor Pharma’ for an equity value of $11.7 Billion, so to increase company’s reach to treatment of kidney disease & iron deficiency. The deal, if completed, will push the value of global M&A in the health-care and pharma sectors past its all-time record.